Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Evexia Wealth LLC

Evexia Wealth LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 4.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,898 shares of the medical instruments supplier’s stock after buying an additional 1,086 shares during the quarter. Becton, Dickinson and Company makes up approximately 2.4% of Evexia Wealth LLC’s investment portfolio, making the stock its 19th largest position. Evexia Wealth LLC’s holdings in Becton, Dickinson and Company were worth $5,668,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Sapient Capital LLC acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth about $1,295,000. Vest Financial LLC raised its position in shares of Becton, Dickinson and Company by 27.5% during the 4th quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock valued at $25,115,000 after buying an additional 22,207 shares during the period. M. Kulyk & Associates LLC lifted its holdings in Becton, Dickinson and Company by 5.1% in the third quarter. M. Kulyk & Associates LLC now owns 16,640 shares of the medical instruments supplier’s stock valued at $4,302,000 after acquiring an additional 809 shares during the last quarter. SG Americas Securities LLC grew its position in Becton, Dickinson and Company by 69.4% in the fourth quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock worth $3,685,000 after acquiring an additional 6,190 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in Becton, Dickinson and Company by 1.1% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 714,114 shares of the medical instruments supplier’s stock worth $174,122,000 after acquiring an additional 7,790 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

Separately, Barclays upped their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $281.40.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.2 %

Shares of BDX traded up $0.56 during midday trading on Tuesday, hitting $237.14. 1,120,070 shares of the stock were exchanged, compared to its average volume of 1,408,706. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The stock has a fifty day simple moving average of $238.27 and a 200 day simple moving average of $239.97. The firm has a market cap of $68.54 billion, a P/E ratio of 52.23, a P/E/G ratio of 1.92 and a beta of 0.45.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The company had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. Becton, Dickinson and Company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the business posted $2.86 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.